Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kessler

Showing results (71-80 of 1,889) with videos related to

Pageof 189
Sort By:
American Heart Journal|April 30, 1999
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspectiveJ M Kessler
The New England Journal of Medicine|June 9, 2001
Controlling tobacco useK M Kessler
Circulation|March 12, 2003
Combining composite endpoints: counterintuitive or a mathematical impossibility?Kenneth M Kessler
European Urology|June 2, 2019
Re: Continuous Low-dose Antibiotic Prophylaxis for Adults with Repeated Urinary Tract Infections (AnTIC): A Randomized, Open-label TrialThomas M Kessler
The Journal of Urology|May 29, 2019
Editorial CommentThomas M Kessler
BJU International|April 30, 2020
Guidelines on urinary incontinence: it is time to join forces!Thomas M Kessler
European Urology|August 7, 2021
Re: Antimicrobial use in a cohort of US nursing homes, 2017Thomas M Kessler
The New England Journal of Medicine|February 24, 2001
Primary prevention of coronary heart disease in women through diet and lifestyleK M Kessler
Circulation|March 15, 2000
Qualification of the concepts of unqualified success and unmitigated failureK M Kessler
Current Opinion in Hematology|October 31, 2000
New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrateC M Kessler
Pageof 189

Showing results (71-80 of 1,889) with videos related to

Sort By:
Pageof 189
American Heart Journal|April 30, 1999
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspectiveJ M Kessler
The New England Journal of Medicine|June 9, 2001
Controlling tobacco useK M Kessler
Circulation|March 12, 2003
Combining composite endpoints: counterintuitive or a mathematical impossibility?Kenneth M Kessler
European Urology|June 2, 2019
Re: Continuous Low-dose Antibiotic Prophylaxis for Adults with Repeated Urinary Tract Infections (AnTIC): A Randomized, Open-label TrialThomas M Kessler
The Journal of Urology|May 29, 2019
Editorial CommentThomas M Kessler
BJU International|April 30, 2020
Guidelines on urinary incontinence: it is time to join forces!Thomas M Kessler
European Urology|August 7, 2021
Re: Antimicrobial use in a cohort of US nursing homes, 2017Thomas M Kessler
The New England Journal of Medicine|February 24, 2001
Primary prevention of coronary heart disease in women through diet and lifestyleK M Kessler
Circulation|March 15, 2000
Qualification of the concepts of unqualified success and unmitigated failureK M Kessler
Current Opinion in Hematology|October 31, 2000
New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrateC M Kessler
Pageof 189